Zydus Pharmaceuticals (USA) Inc., a wholly owned subsidiary of Cadila Healthcare Limited (Cadila), received final USFDA approval to market Nifedipine Extended-Release Tablets USP in strengths of 30 mg, 60 mg, and 90 mg. This was announced by Cadila to the stock exchanges on December 21, 2017.
Cadila Healthcare is a fully-integrated, pharmaceutical company with strong presence in the formulations and CRAMS businesses globally. Its formulations business spans India, US, Europe and emerging markets (mainly Brazil and South Africa). The company derived 34% and 41% revenues from India and the US, respectively in FY17.
The USFDA has granted final approval for Nifedipine Extended-Release Tablets USP in strengths of 30 mg, 60 mg, and 90 mg. The drug is used to treat hypertension (high blood pressure) and angina (chest pain). It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. The group now has more than 180 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is currently trading at Rs429.95, up by Rs9.95 or 2.37% from its previous closing of Rs420 on the BSE. The scrip opened at Rs418.5 and has touched a high and low of Rs434.3 and Rs418.5 respectively. The current market cap of the company is Rs42997.19 crore.
Get more details here:-
PREMIUM FUTURE BUY NSE MFSL CMP AT 488 TARGET 494-500 SL 480.5
ReplyDeleteOUR FIRST TGT 494 ALMOST ACHIEVED IN MFSL BUY CALL, ONCE BOOK PARTIAL PROFIT NOW 493.65 AND TRAIL SL AT COST
free HNI Options Tips
Brilliant desings, I personaly like the one with the slide on the side.
ReplyDeletecomputer data entry